<?xml version='1.0' encoding='utf-8'?>
<document id="23716885"><sentence text="Effect of combination of aripiprazole with carbamazepine and fluvoxamine on liver functions in experimental animals."><entity charOffset="25-37" id="DDI-PubMed.23716885.s1.e0" text="aripiprazole" /><entity charOffset="43-56" id="DDI-PubMed.23716885.s1.e1" text="carbamazepine" /><entity charOffset="61-72" id="DDI-PubMed.23716885.s1.e2" text="fluvoxamine" /><pair ddi="false" e1="DDI-PubMed.23716885.s1.e0" e2="DDI-PubMed.23716885.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23716885.s1.e0" e2="DDI-PubMed.23716885.s1.e1" /><pair ddi="false" e1="DDI-PubMed.23716885.s1.e0" e2="DDI-PubMed.23716885.s1.e2" /><pair ddi="false" e1="DDI-PubMed.23716885.s1.e1" e2="DDI-PubMed.23716885.s1.e1" /><pair ddi="false" e1="DDI-PubMed.23716885.s1.e1" e2="DDI-PubMed.23716885.s1.e2" /></sentence><sentence text="Aripiprazole, a new atypical antipsychotic drug extensively metabolized by enzyme CYP3A4, is found to produce asymptomatic elevation of serum transaminase levels on long-term treatment"><entity charOffset="0-12" id="DDI-PubMed.23716885.s2.e0" text="Aripiprazole" /></sentence><sentence text=" The present study aims to evaluate the hepatotoxic effect of aripiprazole when coprescribed with carbamazepine and fluvoxamine"><entity charOffset="62-74" id="DDI-PubMed.23716885.s3.e0" text="aripiprazole" /><entity charOffset="98-111" id="DDI-PubMed.23716885.s3.e1" text="carbamazepine" /><entity charOffset="116-127" id="DDI-PubMed.23716885.s3.e2" text="fluvoxamine" /><pair ddi="false" e1="DDI-PubMed.23716885.s3.e0" e2="DDI-PubMed.23716885.s3.e0" /><pair ddi="false" e1="DDI-PubMed.23716885.s3.e0" e2="DDI-PubMed.23716885.s3.e1" /><pair ddi="false" e1="DDI-PubMed.23716885.s3.e0" e2="DDI-PubMed.23716885.s3.e2" /><pair ddi="false" e1="DDI-PubMed.23716885.s3.e1" e2="DDI-PubMed.23716885.s3.e1" /><pair ddi="false" e1="DDI-PubMed.23716885.s3.e1" e2="DDI-PubMed.23716885.s3.e2" /></sentence><sentence text="" /><sentence text="The rats were subjected to chronic treatment with two different doses, therapeutic dose (TD) and maximum therapeutic dose (MTD), of aripiprazole in combination with carbamazepine and fluvoxamine"><entity charOffset="132-144" id="DDI-PubMed.23716885.s5.e0" text="aripiprazole" /><entity charOffset="165-178" id="DDI-PubMed.23716885.s5.e1" text="carbamazepine" /><entity charOffset="183-194" id="DDI-PubMed.23716885.s5.e2" text="fluvoxamine" /><pair ddi="false" e1="DDI-PubMed.23716885.s5.e0" e2="DDI-PubMed.23716885.s5.e0" /><pair ddi="false" e1="DDI-PubMed.23716885.s5.e0" e2="DDI-PubMed.23716885.s5.e1" /><pair ddi="false" e1="DDI-PubMed.23716885.s5.e0" e2="DDI-PubMed.23716885.s5.e2" /><pair ddi="false" e1="DDI-PubMed.23716885.s5.e1" e2="DDI-PubMed.23716885.s5.e1" /><pair ddi="false" e1="DDI-PubMed.23716885.s5.e1" e2="DDI-PubMed.23716885.s5.e2" /></sentence><sentence text=" The changes in hepatic function was assessed by various biochemical liver enzyme markers like serum glutamate oxaloacetate transaminase (SGOT), serum glutamate pyruvate transaminase (SGPT), alkaline phosphatase (ALP), total bilirubin, histological studies, and physical parameters (liver weight, liver volume, and body weight)"><entity charOffset="101-123" id="DDI-PubMed.23716885.s6.e0" text="glutamate oxaloacetate" /><entity charOffset="151-169" id="DDI-PubMed.23716885.s6.e1" text="glutamate pyruvate" /><entity charOffset="225-234" id="DDI-PubMed.23716885.s6.e2" text="bilirubin" /><pair ddi="false" e1="DDI-PubMed.23716885.s6.e0" e2="DDI-PubMed.23716885.s6.e0" /><pair ddi="false" e1="DDI-PubMed.23716885.s6.e0" e2="DDI-PubMed.23716885.s6.e1" /><pair ddi="false" e1="DDI-PubMed.23716885.s6.e0" e2="DDI-PubMed.23716885.s6.e2" /><pair ddi="false" e1="DDI-PubMed.23716885.s6.e1" e2="DDI-PubMed.23716885.s6.e1" /><pair ddi="false" e1="DDI-PubMed.23716885.s6.e1" e2="DDI-PubMed.23716885.s6.e2" /></sentence><sentence text="" /><sentence text="The combination of aripiprazole with fluvoxamine at both TD and MTD showed the hepatic damage and significant elevation in serum transaminase level which is supported by histological reports"><entity charOffset="19-31" id="DDI-PubMed.23716885.s8.e0" text="aripiprazole" /><entity charOffset="37-48" id="DDI-PubMed.23716885.s8.e1" text="fluvoxamine" /><pair ddi="false" e1="DDI-PubMed.23716885.s8.e0" e2="DDI-PubMed.23716885.s8.e0" /><pair ddi="false" e1="DDI-PubMed.23716885.s8.e0" e2="DDI-PubMed.23716885.s8.e1" /></sentence><sentence text=" The coadministration of aripiprazole with carbamazepine leads to significant decrease in blood concentration of aripiprazole possibly due to induction of enzyme CYP3A4 resulting in loss or reduction of clinical efficacy"><entity charOffset="25-37" id="DDI-PubMed.23716885.s9.e0" text="aripiprazole" /><entity charOffset="43-56" id="DDI-PubMed.23716885.s9.e1" text="carbamazepine" /><entity charOffset="113-125" id="DDI-PubMed.23716885.s9.e2" text="aripiprazole" /><pair ddi="false" e1="DDI-PubMed.23716885.s9.e0" e2="DDI-PubMed.23716885.s9.e0" /><pair ddi="false" e1="DDI-PubMed.23716885.s9.e0" e2="DDI-PubMed.23716885.s9.e1" /><pair ddi="false" e1="DDI-PubMed.23716885.s9.e0" e2="DDI-PubMed.23716885.s9.e2" /><pair ddi="false" e1="DDI-PubMed.23716885.s9.e1" e2="DDI-PubMed.23716885.s9.e1" /><pair ddi="false" e1="DDI-PubMed.23716885.s9.e1" e2="DDI-PubMed.23716885.s9.e2" /></sentence><sentence text="" /><sentence text="There would be an accumulation of aripiprazole when coadministered with fluvoxamine, a known inhibitor of CYP3A4, leading to hepatic damage and reduction in aripiprazole when administered along with carbamazepine"><entity charOffset="34-46" id="DDI-PubMed.23716885.s11.e0" text="aripiprazole" /><entity charOffset="72-83" id="DDI-PubMed.23716885.s11.e1" text="fluvoxamine" /><entity charOffset="157-169" id="DDI-PubMed.23716885.s11.e2" text="aripiprazole" /><entity charOffset="199-212" id="DDI-PubMed.23716885.s11.e3" text="carbamazepine" /><pair ddi="false" e1="DDI-PubMed.23716885.s11.e0" e2="DDI-PubMed.23716885.s11.e0" /><pair ddi="false" e1="DDI-PubMed.23716885.s11.e0" e2="DDI-PubMed.23716885.s11.e1" /><pair ddi="false" e1="DDI-PubMed.23716885.s11.e0" e2="DDI-PubMed.23716885.s11.e2" /><pair ddi="false" e1="DDI-PubMed.23716885.s11.e0" e2="DDI-PubMed.23716885.s11.e3" /><pair ddi="false" e1="DDI-PubMed.23716885.s11.e1" e2="DDI-PubMed.23716885.s11.e1" /><pair ddi="false" e1="DDI-PubMed.23716885.s11.e1" e2="DDI-PubMed.23716885.s11.e2" /><pair ddi="false" e1="DDI-PubMed.23716885.s11.e1" e2="DDI-PubMed.23716885.s11.e3" /><pair ddi="false" e1="DDI-PubMed.23716885.s11.e2" e2="DDI-PubMed.23716885.s11.e2" /><pair ddi="false" e1="DDI-PubMed.23716885.s11.e2" e2="DDI-PubMed.23716885.s11.e3" /></sentence><sentence text=" Therefore, aripiprazole with fluvoxamine and carbamazepine should be coprescribed with caution"><entity charOffset="12-24" id="DDI-PubMed.23716885.s12.e0" text="aripiprazole" /><entity charOffset="30-41" id="DDI-PubMed.23716885.s12.e1" text="fluvoxamine" /><entity charOffset="46-59" id="DDI-PubMed.23716885.s12.e2" text="carbamazepine" /><pair ddi="false" e1="DDI-PubMed.23716885.s12.e0" e2="DDI-PubMed.23716885.s12.e0" /><pair ddi="false" e1="DDI-PubMed.23716885.s12.e0" e2="DDI-PubMed.23716885.s12.e1" /><pair ddi="false" e1="DDI-PubMed.23716885.s12.e0" e2="DDI-PubMed.23716885.s12.e2" /><pair ddi="false" e1="DDI-PubMed.23716885.s12.e1" e2="DDI-PubMed.23716885.s12.e1" /><pair ddi="false" e1="DDI-PubMed.23716885.s12.e1" e2="DDI-PubMed.23716885.s12.e2" /></sentence><sentence text=" The patients should be monitored for signs of adverse effects like hepatic damage or decreased efficacy of these drugs" /><sentence text="" /></document>